Can you get Wegovy if you are not obese?

The biggest misconception: Wegovy is only for people with obesity

Most people searching this question have heard Wegovy described as an 'obesity drug' and assume a BMI under 30 closes the door entirely. That is not what the licence says. The MHRA-approved indication for Wegovy (semaglutide 2.4mg injection) covers adults with a BMI of 27 or above alongside at least one weight-related comorbidity, conditions like raised blood pressure, dyslipidaemia, type 2 diabetes, or obstructive sleep apnoea all count. A BMI of 28 with clinically confirmed hypertension, for example, sits squarely within the licensed indication.

What the licence does not permit is treatment for people in the healthy-weight range or those seeking to lose a small amount for purely cosmetic reasons. The MHRA has been clear on this point: GLP-1 medicines are not assessed or approved for quick or cosmetic weight loss. That distinction matters because it shapes every legitimate prescriber's decision-making. If you are thinking about whether Wegovy is suitable when you are not obese, our Wegovy overview explains the full picture of the treatment.

It is worth being honest about something: if you have landed on this page because you are worried you will not qualify, that uncertainty is genuinely common. The BMI system is imperfect, and a number alone rarely tells a complete clinical story. A prescriber looks at the whole picture.

What the NICE guidance adds, and why NHS access is different

The licensed indication and the NHS eligibility criteria are two separate things, and confusing them is easy. The MHRA licence sets the minimum bar for private prescribing. NICE's appraisal of semaglutide for weight management (TA875) narrows NHS access further: it recommends the treatment only within specialist weight management services, for a maximum of two years, and typically for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with the adjusted 2.5 kg/m² lower threshold applying for certain ethnic backgrounds.

In practice, that means the NHS route is unlikely to be available to someone with a BMI of 27–29.9 in the near future, even if they meet the licence criteria for private treatment. Getting Wegovy through a regulated private pharmacy is the realistic route for people in the 27–29.9 BMI bracket who have a qualifying condition. Private prescribing follows the licensed indication rather than the NICE NHS thresholds, though the prescriber still conducts a full clinical assessment. You can read the NICE TA875 guidance on semaglutide directly if you want the detail behind the NHS criteria.

What a qualifying weight-related condition actually means

The phrase 'weight-related comorbidity' sounds clinical, but the list is broader than many people expect. Conditions that typically qualify include type 2 diabetes, prediabetes, hypertension (raised blood pressure), dyslipidaemia (abnormal cholesterol or triglycerides), obstructive sleep apnoea, and certain cardiovascular risk factors. Osteoarthritis linked to excess weight has also been discussed in clinical contexts, though prescribers assess this individually.

What this means practically: if your GP has ever noted raised blood pressure, referred you about cholesterol, or flagged prediabetes on a blood test, you may well have a qualifying condition you have not consciously labelled as such. A prescriber will ask. They will also check that treatment is safe given your full medical history, certain conditions, including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis, require careful consideration before semaglutide is appropriate. The NHS semaglutide medicines page has a plain-English summary of who should not use it.

For context on whether you have to be obese to get Wegovy and how the prescription process works in practice, the weight-loss treatment overview is a useful starting point before a consultation.

What happens next if you think you might qualify

If your BMI is between 27 and 29.9 and you have a weight-related health condition, the sensible first step is a clinical consultation. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not an automated system) on the same day it is submitted. They review your answers, your medical history, and your eligibility against the licensed criteria before any decision is made. There is no obligation, and the consultation is free.

Semaglutide is a prescription-only medicine. That means a qualified prescriber must decide whether it is right for you; no pharmacy can or should dispense it on request alone. If you want to understand what stopping Wegovy involves if you take it, including what private treatment typically costs, the cost and process breakdown for Wegovy covers what private treatment typically involves. Treatment at the lower BMI threshold is possible, it just requires that clinical step first, and if you are also thinking ahead, our guide on how you get off Wegovy when the time comes is worth reading before you start. Speak to our prescribers if you want to find out whether you are eligible.